Talc Settlement Takes Shape
Johnson & Johnson says it will pay an estimated $5.5 billion to put an end to tens of thousands of lawsuits that claim its baby powder and other talc products caused ovarian cancer. The company confirmed the move on Monday, and if it holds, it could finally close a legal chapter that has trailed J&J for 10 years. For a company that has spent a decade fighting the same battle in different courtrooms, this feels less like a routine settlement and more like an attempt to simply move on.
Claims Near Resolution
The deal covers roughly 76,000 claims, spanning cases consolidated in federal court in New Jersey as well as related state court lawsuits, and together these represent almost every talc claim J&J still had on its plate. Most of the earlier mesothelioma-related cases had already been settled separately. Lawyers representing the plaintiffs called it a fair result after years of back and forth, though there is a catch. The settlement only becomes final once 95% of eligible ovarian cancer claimants agree to it.
J&J's own litigation chief maintained that the claims lacked merit, but admitted the company would rather settle than keep fighting case by case. On the financial side, J&J expects to pay around $3 billion in 2027, with more to follow in 2028. And because the agreement has no hard cap, one attorney involved in the negotiations believes the final bill could climb past $7 billion depending on how many claimants opt in.
Legal Risk Gets Priced
Interestingly, this settlement comes right after a run of courtroom wins for J&J. The company had recently prevailed in several individual trials, gotten some plaintiffs' lawyers disqualified, and seen judges push back on the scientific evidence being used against it. Just last week, a federal judge questioned whether individual plaintiffs could even prove that talc specifically caused their cancer, a ruling that likely gave J&J more leverage at the negotiating table.
Before all this, the company had tried 3 separate times to resolve the litigation through bankruptcy filings using a shell subsidiary, but courts kept dismissing the strategy. That approach was finally dropped when the lawsuits resumed in March 2025 after sitting on hold for 3 years. Unlike those failed bankruptcy attempts, this settlement only deals with claims that already exist, meaning future lawsuits are still possible. What it does change is speed. Instead of dragging out for another decade, claims are now expected to be paid within 18 months.
Certainty Carries A Price
At its core, this is J&J choosing to pay a large sum today rather than continue absorbing years of unpredictable legal risk. With most existing claims covered and payments set to begin in 2027, the company finally has something closer to a defined path forward, even though new talc lawsuits could still surface down the line. After a decade of legal uncertainty, this settlement may end up being one of the more consequential decisions J&J has made in recent memory.
The $5.5 billion settlement may close thousands of claims, but the bigger question is how much certainty is worth to corporate balance sheets.